Symposium On Immuno-Oncology In Prostate Cancer
Current and Future Trends
Recorded: June 24, 2021
Program Description
Topics will cover the landscape of immunotherapy options in prostate cancer; novel mechanisms of action; BiTE antibodies; Car-T Cell Therapy; the use of pembrolizumab in advanced prostate cancer, and future perspectives. Sponsored by AMGEN.
Faculty presenters:
- Saul Priceman, PhD City of Hope Medical Center – Presenter and Moderator
- Rahul Aggarwal, MD University of California,
- Charles Drake, MD, PhD New York-Presbyterian/Columbia
- Lawrence Fong, MD University of California, San Francisco
- James Gulley, MD, PhD National Institutes of Health
- John Lee, MD, PhD Fred Hutchinson Cancer Center, Seattle
- Vivek Narayen, MD, MS University of Pennsylvania
- Sumit Subudhi, MD, PhD M.D. Anderson Cancer, Houston
Video presentations
- Introduction – Video
Merel Nissenberg, Esq., President, NASPCC - Introductory Remarks – Video
Saul Priceman, PhD - Redirecting T-Cells for Prostate Cancer Immunotherapy – Video
Lawrence Fong, MD - CAR-T Development in Sub-Types of Prostate Cancer: How Mechanistic Biology Impacts Future Therapies – Video
John Lee, MD, PhD - Chimeric Antigen Receptor T-Cell Therapies for Advanced Prostate Cancer: Clinical Trials (and Tribulations) – Video
Vivek Narayen, MD, MS - Advancing CAR-T Cells for Prostate Cancer – Video
Saul Priceman, PhD - Panel Discussion
- Upcoming Clinical Trial of DLL3/CF3 BiTE in Neuroendocrine Prostate Cancer – Video
Rahul Aggarwal, MD - Anti-CTLA-4-Therapy in Prostate Cancer – Video
Sumit Subudhi, MD, PhD - The QuEST for an Effective Immunotherapy for Prostate Cancer – Video
James Gulley, MD, PhD - Allogenic Approaches to Cell Therapy for Tumors of Various Sorts – Video
Charles Drake, MD, PhD - Panel Discussion
- Closing Remarks
Handouts in PDF Format
CAR-T Development in Sub-Types of Prostate Cancer: How Mechanistic Biology Impacts Future Therapies | John Lee, MD, PhD
View
Chimeric Antigen Receptor T-Cell Therapies for Advanced Prostate Cancer: Clinical Trials (and Tribulations) | Vivek Narayen, MD, MS
View